

Global Plasma Fractionation Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

<https://marketpublishers.com/r/GCF17155F79EN.html>

Date: November 2017

Pages: 201

Price: US\$ 4,400.00 (Single User License)

ID: GCF17155F79EN

Abstracts

Global Plasma Fractionation Market:

Global plasma fractionation market estimated to be valued US\$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for plasma fractionation is projected to reach US\$ XX Mn by 2023.

Plasma fractionation refers to the process of separation, extraction, and purification of plasma. Human plasma contains the large variety of proteins, however, only a few of these proteins are help in producing therapeutic plasma products. Plasma is used in prevention and treatment of various life threatening diseases caused by trauma, immunologic disorders, and infections. Plasma fractionation process is majorly used in treating protein deficiency condition in healthcare applications. The proteins extracted from the plasma are majorly categorized into three main classes: immunoglobulins which are useful in treatment of autoimmune disorders and increasing the immune response of the body, clotting factors which are help in treatment of blood disorders such as haemophilia, and the albumins which are useful in conditions of decreased albumin levels or during fluid loss. Plasma fractionation process is carried by different criteria such as solubility of the products, and their physical and chemical conditions such as ionic strengths, pH levels, and temperature, etc. The removal or inactivation of viruses and prions is an important function of plasma fractionation, and it can be carried by various mechanical and physical treatments for virus inactivation such as nano filtration, detergent/solvent treatment, heat treatment, chromatography centrifugation, ultrafiltration, and sterile filtration in order to achieve homogeneity of plasma, and

reduce the risks of viral transmissions.

Plasma fractionation market expected to grow at significant rate over the forecast period due to rise in the incidence of immune and bleeding disorders, increase in the use of alpha-1 antitrypsin and immunoglobulin, rise in prevalence of Alpha-1 Antitrypsin Deficiency (AATD), emphysema, and haemophilia. In addition, development in plasma techniques and plasma utilization are the key factors expected to boost the plasma fractionation market. However, high cost for the plasma products, adverse effects associated with the plasma fractionation products, lack of reimbursement policies, stringent regulatory policies, and increase in the recombinant coagulation factors might hinder the growth of plasma fractionation market over the forecast timeframe.

Global plasma fractionation market segmented based on the product type, application, and end user

Based on product type, global plasma fractionation market segmented into the following:

Albumin

Immunoglobulin

Intravenous immunoglobulin

Subcutaneous immunoglobulin

Others

Coagulation factor concentrates

Factor viii

Factor ix

Factor xiii

Prothrombin complex concentrates

Von Willebrand factor (VWF)

Protease inhibitors

Other plasma fractionation products

Based on application, global plasma fractionation market segmented into the following:

Neurology

Haematology

Immunology

Rheumatology

Haemato-oncology

Critical Care

Pulmonology

Others

Based on end-user, global plasma fractionation market segmented into the following:

Hospitals

Clinics

Academic Institutes

Clinical Research Laboratories

Several international players are actively involved in the development of global plasma fractionation products. In 2015, immunoglobulins commanded for the largest share of the global plasma fractionation market due to rise in prevalence and incidence

autoimmune disorders (according to International Journal of Celiac Disease, 2015 the world prevalence and incidence of Autoimmune Diseases are increasing, the global net percent increased per year prevalence and incidence of autoimmune disorders were 12.5 ± 7.9 and 19.1 ± 43.1 respectively). However, the protease inhibitors are expected to highest growth in the forecasting period, due to increasing use of proteases for respiratory diseases and growing application in various diseases. Partnerships, agreements, new products launch, collaborations, acquisitions and mergers, joint ventures, are being adopted by various key players in the global plasma fractionation market. For instance, in 2003, Probitas Pharma acquired Alpha Therapeutic from Mitsubishi Pharma, similarly, Octapharma acquired Mexican fractionator Probifasa S.A. de C.V. for developing the plasma products.

Geographically, global plasma fractionation market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the global plasma fractionation market followed by Europe and Asia-Pacific. The largest share of North-America in global plasma fractionation market is due to increasing use of immunoglobulins in neurological diseases and increasing use of prophylaxis treatments for chronic diseases in this region (According to Centres of Disease Control (CDC), in 2012, chronic diseases were one of the leading causes of death and disability in the U.S., with an estimated 117 Mn adults suffering from some form of chronic disease). Europe is the second largest region for global plasma fractionation market due to the rise in aging population and increase in the prevalence of chronic diseases. However, Asia-Pacific is expected to register significant growth rate over the forecast owing to the increasing aging population, growing using of albumin and immunoglobulin, and an increasing focus on better diagnosis, prophylactic treatments, medical research, and organ transplantations in Asia-Pacific regions.

Some of the players in plasma fractionation market are Grifols S.A (Spain), CSL Ltd. (Australia), Shire (Ireland), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), China Biologic Products, Inc. (China), Biotest AG (OGEL GmbH) (Germany), LFB S.A (France), and Sanquin (Netherlands) to name a few.

In 2017, Grifols opens new lines of research with the acquisition of a 44% stake in GigaGen for US\$ 35Mn

In 2015, Baxalta receives CHMP positive opinion for sanquin to begin production, purification and enhancing global supply of plasma based therapies

In 2014, CSL Behring launched US\$ 450 Mn capacity expansion to meet growing need for life-saving, and life improving therapies in plasma fractionation

REPORT OUTLINE:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings and their key strategies

The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenari

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL PLASMA FRACTIONATION MARKET INTRODUCTION

2.1. Global Plasma Fractionation Market – Taxonomy

2.2. Global Plasma Fractionation Market – Definitions

2.2.1. Product Type

2.2.2. End User

3. GLOBAL PLASMA FRACTIONATION MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Plasma Fractionation Market Dynamics – Factors Impact Analysis

3.6. Global Plasma Fractionation Market– Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

4. GLOBAL PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Albumin

5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Immunoglobulins

5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Coagulation factor concentrates

5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

5.4. Protease inhibitors

5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.4.3. Market Opportunity Analysis

5.5. Other Plasma Fractionation Products

5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.5.3. Market Opportunity Analysis

6. GLOBAL PLASMA FRACTIONATION MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Neurology

6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Hematology

6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Immunology

6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

6.4. Rheumatology

6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.4.3. Market Opportunity Analysis

6.5. Haemato-oncology

6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.5.3. Market Opportunity Analysis

6.6. Critical Care

- 6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.6.3. Market Opportunity Analysis

6.7. Pulmonology

- 6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.7.3. Market Opportunity Analysis

6.8. Others

- 6.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.8.3. Market Opportunity Analysis

7. GLOBAL PLASMA FRACTIONATION MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospitals

- 7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.1.3. Market Opportunity Analysis

7.2. Clinics

- 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.2.3. Market Opportunity Analysis

7.3. Academic Institutes

- 7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.3.3. Market Opportunity Analysis

7.4. Clinical Research Laboratories

- 7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.4.3. Market Opportunity Analysis

8. GLOBAL PLASMA FRACTIONATION MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America

- 8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

8.6. Global Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user, and Region, 2017 – 2023

9. NORTH AMERICA PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1.1. Albumin

9.1.1.2. Immunoglobulin

9.1.1.2.1. Intravenous immunoglobulin

9.1.1.2.2. Subcutaneous immunoglobulin

9.1.1.2.3. Others

9.1.1.3. Coagulation Factor Concentrates

9.1.1.3.1. Factor viii

9.1.1.3.2. Factor ix

9.1.1.3.3. Factor xiii

9.1.1.3.4. Prothrombin complex concentrates

9.1.1.3.5. Von Willebrand factor (VWF)

9.1.1.4. Protease Inhibitors

9.1.1.5. Other Plasma Fractionation Products

9.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.2.1. Neurology

9.1.2.2. Hematology

9.1.2.3. Immunology

9.1.2.4. Rheumatology

9.1.2.5. Haemato-oncology

9.1.2.6. Critical Care

9.1.2.7. Pulmonology

9.1.2.8. Others

9.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.3.1. Hospitals

9.1.3.2. Clinics

9.1.3.3. Academic Institutes

9.1.3.4. Clinical Research Laboratories

9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.1.4.1. U.S.

9.1.4.2. Canada

9.1.5. North America Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user, and Country, 2017 – 2023

9.1.6. North America Plasma Fractionation Market Dynamics – Trends

10. EUROPE PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1.1. Albumin

10.1.1.2. Immunoglobulin

10.1.1.2.1. Intravenous immunoglobulin

10.1.1.2.2. Subcutaneous immunoglobulin

10.1.1.2.3. Others

10.1.1.3. Coagulation Factor Concentrates

10.1.1.3.1. Factor viii

10.1.1.3.2. Factor ix

10.1.1.3.3. Factor xiii

10.1.1.3.4. Prothrombin complex concentrates

10.1.1.3.5. Von Willebrand factor (VWF)

10.1.1.4. Protease Inhibitors

10.1.1.5. Other Plasma Fractionation Products

10.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. Neurology

10.1.2.2. Hematology

10.1.2.3. Immunology

10.1.2.4. Rheumatology

10.1.2.5. Haemato-oncology

10.1.2.6. Critical Care

10.1.2.7. Pulmonology

10.1.2.8. Others

10.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Hospitals

10.1.3.2. Clinics

10.1.3.3. Academic Institutes

10.1.3.4. Clinical Research Laboratories

10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Germany

10.1.4.2. UK

10.1.4.3. France

10.1.4.4. Spain

10.1.4.5. Italy

10.1.4.6. Russia

10.1.4.7. Poland

10.1.4.8. Rest of Europe

10.1.5. Europe Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user Type, and Country, 2017 – 2023

10.1.6. Europe Plasma Fractionation Market Dynamics – Trends

11. ASIA-PACIFIC PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1.1. Albumin

11.1.1.2. Immunoglobulin

11.1.1.2.1. Intravenous immunoglobulin

- 11.1.1.2.2. Subcutaneous immunoglobulin
- 11.1.1.2.3. Others
- 11.1.1.3. Coagulation Factor Concentrates
 - 11.1.1.3.1. Factor viii
 - 11.1.1.3.2. Factor ix
 - 11.1.1.3.3. Factor xiii
 - 11.1.1.3.4. Prothrombin complex concentrates
 - 11.1.1.3.5. Von Willebrand factor (VWF)
- 11.1.1.4. Protease Inhibitors
- 11.1.1.5. Other Plasma Fractionation Products
- 11.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.1.2.1. Neurology
 - 11.1.2.2. Hematology
 - 11.1.2.3. Immunology
 - 11.1.2.4. Rheumatology
 - 11.1.2.5. Haemato-oncology
 - 11.1.2.6. Critical Care
 - 11.1.2.7. Pulmonology
 - 11.1.2.8. Others
- 11.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.1.3.1. Hospitals
 - 11.1.3.2. Clinics
 - 11.1.3.3. Academic Institutes
 - 11.1.3.4. Clinical Research Laboratories
- 11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 11.1.4.1. Japan
 - 11.1.4.2. China
 - 11.1.4.3. India
 - 11.1.4.4. ASEAN
 - 11.1.4.5. Australia & New Zealand
 - 11.1.4.6. Rest of Asia-Pacific
- 11.1.5. Asia-Pacific Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user Type, and Country, 2017 – 2023
- 11.1.6. Asia-Pacific Plasma Fractionation Market Dynamics – Trends

12. LATIN AMERICA PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1.1. Albumin

12.1.1.2. Immunoglobulin

12.1.1.2.1. Intravenous immunoglobulin

12.1.1.2.2. Subcutaneous immunoglobulin

12.1.1.2.3. Others

12.1.1.3. Coagulation Factor Concentrates

12.1.1.3.1. Factor viii

12.1.1.3.2. Factor ix

12.1.1.3.3. Factor xiii

12.1.1.3.4. Prothrombin complex concentrates

12.1.1.3.5. Von Willebrand factor (VWF)

12.1.1.4. Protease Inhibitors

12.1.1.5. Other Plasma Fractionation Products

12.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Neurology

12.1.2.2. Hematology

12.1.2.3. Immunology

12.1.2.4. Rheumatology

12.1.2.5. Haemato-oncology

12.1.2.6. Critical Care

12.1.2.7. Pulmonology

12.1.2.8. Others

12.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Hospitals

12.1.3.2. Clinics

12.1.3.3. Academic Institutes

12.1.3.4. Clinical Research Laboratories

12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Brazil

12.1.4.2. Mexico

12.1.4.3. Argentina

12.1.4.4. Venezuela

12.1.4.5. Rest of Latin America

12.1.5. Latin America Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user Type, and Country, 2017 – 2023

12.1.6. Latin America Plasma Fractionation Market Dynamics – Trends

13. MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1.1. Albumin

13.1.1.2. Immunoglobulin

13.1.1.2.1. Intravenous immunoglobulin

13.1.1.2.2. Subcutaneous immunoglobulin

13.1.1.2.3. Others

13.1.1.3. Coagulation Factor Concentrates

13.1.1.3.1. Factor viii

13.1.1.3.2. Factor ix

13.1.1.3.3. Factor xiii

13.1.1.3.4. Prothrombin complex concentrates

13.1.1.3.5. Von Willebrand factor (VWF)

13.1.1.4. Protease Inhibitors

13.1.1.5. Other Plasma Fractionation Products

13.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.2.1. Neurology

13.1.2.2. Hematology

13.1.2.3. Immunology

13.1.2.4. Rheumatology

13.1.2.5. Haemato-oncology

13.1.2.6. Critical Care

13.1.2.7. Pulmonology

13.1.2.8. Others

13.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.3.1. Hospitals

13.1.3.2. Clinics

13.1.3.3. Academic Institutes

- 13.1.3.4. Clinical Research Laboratories
- 13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 13.1.4.1. Gulf Cooperation Council (GCC) Countries
 - 13.1.4.2. Israel
 - 13.1.4.3. South Africa
 - 13.1.4.4. Rest of MEA
- 13.1.5. MEA Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user, and Country, 2017 – 2023
- 13.1.6. MEA Plasma Fractionation Market Dynamics – Trends

14. COMPETITION LANDSCAPE

- 14.1. Strategic Dashboard of Top Market Players
- 14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
 - 14.2.1. Grifols S.A (Spain)
 - 14.2.2. CSL Ltd. (Australia)
 - 14.2.3. Shire (Ireland)
 - 14.2.4. Octapharma AG (Switzerland)
 - 14.2.5. Kedrion S.p.A (Italy)
 - 14.2.6. China Biologic Products, Inc. (China)
 - 14.2.7. Biotest AG (OGEL GmbH) (Germany)
 - 14.2.8. LFB S.A (France)
 - 14.2.9. Sanquin (Netherlands)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Global Plasma Fractionation Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/GCF17155F79EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCF17155F79EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

